Lurbinectedin in everyday care for small cell lung cancer
Original title: Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already approved and in use for this cancer.
The short version
A drug already approved for small cell lung cancer helped some patients in everyday care, with side effects doctors could manage.
What was studied. This study followed 267 people with small cell lung cancer who had been treated before. All of them got a drug called lurbinectedin. It was a phase 4 study done in regular care, not a tightly controlled trial.
What they found. The cancer shrank in 29% of the 189 patients who were checked. It shrank in 33% of people getting it as their second treatment. People whose cancer had spread to the brain did worse, 17% compared with 32%. Typical time before the cancer grew again was 3.3 months, and typical survival was 7.6 months. Side effects from the drug were seen in 88 patients, and 21 stopped the drug because of them.
What this means, and what it doesn't
What it could mean: This drug is already approved, so a doctor can talk about it today. These results come from a wide mix of real patients. They suggest it can help some people whose cancer came back. The benefit looked smaller for people with cancer in the brain.
What it doesn't mean: This does not mean the drug is a cure. The cancer shrank in some people, not in most. The gains here were counted in months, not years. There was no comparison group, so this cannot prove the drug beats other choices. What happened to this group may not be what happens to you.
Source: PubMed, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.